Glycated albumin and the risk of chronic kidney disease in subjects with Type 2 Diabetes: A study in North Indian Population

Aim

Glycated albumin (GA) suggested being alternative glycemic marker than haemoglobin A1C (HbA1c) in patients with chronic kidney diseases (CKD). We investigated the association between GA and the progression of diabetic nephropathy (DN) in T2DM subjects.

Methods

We recruited T2DM subjects with different stages of CKD who had regularly measured serum creatinine and estimated glomerular filtration rates (eGFR) according to Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, HbA1c consecutively every 3 months along with GA levels and other anthropometric and demographic measurements. We grouped age and sex matched subjects into the CKD progression, Group I healthy subjects (n?=?100, M: F;50:50). Group II T2DM subjects with eGFR ≥90?mL/min (n?=?167,?M:F; 76:91). Group III of T2DM patients with eGFR 60–89?mL/min (n?=?91,?M:F; 44:47). Group IV T2DM subjects with eGFR 30–59?mL/min (n?=?68,?M:F;31:37). Group V T2DM with eGFR?≤?29?mL/min (n?=?21, M:F; 13:8).

Results

Pearson’s correlation analysis between glycated albumin and biochemical parameters were established in all subjects. GA/HbA1c ratio increases with poor glycemic control except for nephrosis state.

Conclusion

Mean GA levels were more closely associated with DN progression than mean HbA1c in subjects with T2DM and can be implemented as an alternative diagnostic marker in nephropathy.